Infectious Disease

The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.

The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.

Researchers found a total of 12 symptoms that contributed to the long COVID scoring system.

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.

The FDA approved Paxlovid™ for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe disease.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

The US health care provider community continues to do its collective best to cope with the protean condition that is long COVID, according to recent poll findings.

Vowst is the first and only FDA-approved orally administered microbiota-based therapeutic for the prevention of recurrent C. diff infection in adults.

Your daily dose of clinical news you may have missed.

Results from a prospective birth cohort study show an age-dependent association between RSV infection during infancy and childhood asthma.

When combined, fluvoxamine and inhaled budesonide appear more likely than either agent alone to reduce risk of early COVID-19 becoming severe, say TOGETHER investigators.

The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.

Onset of the 2022-2023 RSV season and its end were closer to historical patterns but atypical circulation may continue, say researchers writing in MMWR.

Vaccine side effects are usually trouble when they make the news. But sometimes, an unexpected result has merit. Find out more.

Universal vaccination against chickenpox with a live-attenuated varicella vaccine began 25 years ago. Were concerns about future shingles outbreaks borne out?

Your daily dose of clinical news you may have missed.

Adding paired serology and sputum to nasal swab/nasopharyngeal swabs RT-PCR increased RSV detection by 50% to 66% on average, respectively.

Drug-resistant cases of Candida auris continue to spread across the US after an alarming 95% rise in cases of the fungal infection in 2021.

The 5-in-1 vaccine candidate, if approved, would provide the broadest meningococcal serogroup coverage and simplify the vaccination schedule.

The FDA authorized Pfizer's bivalent vaccine as a booster dose for children aged under 5 years who received 3 doses of monovalent vaccine.

Your daily dose of clinical news you may have missed.

ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.

The VRBPAC vote that the GSK data support the vaccine's efficacy was unanimous and on safety the vote was 10-2. PDUFA date set for May, 2023.

The first-of-its kind combination home-based test matched lab-based PCR tests for identification of influenza A and B and COVID-19.